Nestor Emmanuel Diaz Martinez

Dr. Nestor Emmanuel Diaz Martinez

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Regenerative Therapy
Verified
Journal Article
Open access
VVValeria Valadez-Barba
Valeria Valadez-Barba
ACA. Cota-Coronado
A. Cota-Coronado
OHO.R. Hernández-Pérez
O.R. Hernández-Pérez
PLPavel Lugo
Pavel Lugo
EPEduardo Padilla-Camberos
Eduardo Padilla-Camberos
NMNestor Emmanuel Diaz Martinez
Nestor Emmanuel Diaz Martinez
Neurodegenerative disorders such as Parkinson's and Alzheimer's disease, are fundamental health concerns all around the world. The development of novel treatments and new techniques to address these disorders, are being actively studied by researchers and medical personnel. In the present review we will discuss the application of induced Pluripotent Stem Cells (iPSCs) for cell-therapy replacement and disease modelling. The aim of iPSCs is to restore the functionality of the damaged tissue by replacing the impaired cells with competitive ones. To achieve this objective, iPSCs can be properly differentiated into virtually any cell fate and can be strongly translated into human health via in vitro and in vivo disease modeling for the development of new therapies, the discovery of biomarkers for several disorders, the elaboration and testing of new drugs as novel treatments, and as a tool for personalized medicine.

27 May 2019 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
PDF file
ACAgustin Cota-Coronado
Agustin Cota-Coronado
NMNestor Emmanuel Diaz Martinez
Nestor Emmanuel Diaz Martinez
EPEduardo Padilla-Camberos
Eduardo Padilla-Camberos
The translational gap to treatments based on gene therapy has been reduced in recent years because of improvements in gene editing tools, such as the CRISPR/Cas9 system and its variations. This has allowed the development of more precise therapies for neurodegenerative diseases, where access is privileged. As a result, engineering of complexes that can access the central nervous system (CNS) with the least potential inconvenience is fundamental. In this review article, we describe current alternatives to generate systems based on CRISPR/Cas9 that can cross the blood–brain barrier (BBB) and may be used further clinically to improve treatment for neurodegeneration in Parkinson’s and Alzheimer’s disease (AD).

27 September 2016 in Plant Foods for Human Nutrition
Verified
Journal Article
Open access
PDF file
AMAna Laura Márquez-Aguirre
Ana Laura Márquez-Aguirre
Rosa María Camacho-RuizRosa María Camacho-Ruiz
Rosa María Camacho-Ruiz
YGYanet Karina Gutierrez-Mercado
Yanet Karina Gutierrez-Mercado
EPEduardo Padilla-Camberos
Eduardo Padilla-Camberos
MGM. González-Ávila
M. González-Ávila
Daniel Ortuño-SahagúnDaniel Ortuño-Sahagún
Daniel Ortuño-Sahagún
Fructans from agave have received specific attention because of their highly branched fructan content. We have previously reported that the degree of polymerization (dp) influences their biological activity. Therefore, the aim of this study was to investigate the effect of unfractionated and fractionated fructans (higher and lower dps) from Agave tequilana in high-fat diet-induced (HFD) obese mice. Fructans with a lower dp (HFD+ScF) decreased weight gain by 30 %, body fat mass by 51 %, hyperglycemia by 25 % and liver steatosis by 40 %. Interestingly, unfractionated fructans (HFD+F) decreased glucose and triglycerides (TG), whereas fractionated fructans with a higher dp (HFD+LcF) decreased TG but not glucose; in contrast, HFD+ScF decreased glucose but not TG. Our findings suggest that both higher and lower dp agave fructans have complementary effects in metabolic disorders related to obesity. These findings may contribute to the development of improved food supplements with a specific ratio combination of fructans with different dps.

1 September 2015 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
AMAna Laura Márquez-Aguirre
Ana Laura Márquez-Aguirre
Alejandro CanalesAlejandro Canales
Alejandro Canales
EPE. Padilla-Camberos
E. Padilla-Camberos
HEHugo Esquivel-Solís
Hugo Esquivel-Solís
NMNestor Emmanuel Diaz Martinez
Nestor Emmanuel Diaz Martinez
Diabetes mellitus represents a serious public health problem owing to its global prevalence in the last decade. The causes of this metabolic disease include dysfunction and/or insufficient number of β cells. Existing diabetes mellitus treatments do not reverse or control the disease. Therefore, β-cell mass restoration might be a promising treatment. Several restoration approaches have been developed: inducing the proliferation of remaining insulin-producing cells, de novo islet formation from pancreatic progenitor cells (neogenesis), and converting non-β cells within the pancreas to β cells (transdifferentiation) are the most direct, simple, and least invasive ways to increase β-cell mass. However, their clinical significance is yet to be determined. Hypothetically, β cells or islet transplantation methods might be curative strategies for diabetes mellitus; however, the scarcity of donors limits the clinical application of these approaches. Thus, alternative cell sources for β-cell replacement could include embryonic stem cells, induced pluripotent stem cells, and mesenchymal stem cells. However, most differentiated cells obtained using these techniques are functionally immature and show poor glucose-stimulated insulin secretion compared with native β cells. Currently, their clinical use is still hampered by ethical issues and the risk of tumor development post transplantation. In this review, we briefly summarize the current knowledge of mouse pancreas organogenesis, morphogenesis, and maturation, including the molecular mechanisms involved. We then discuss two possible approaches of β-cell mass restoration for diabetes mellitus therapy: β-cell regeneration and β-cell replacement. We critically analyze each strategy with respect to the accessibility of the cells, potential risk to patients, and possible clinical outcomes.

12 August 2021 in Materials
Verified
Journal Article
Open access
PDF file
EPEduardo Padilla-Camberos
Eduardo Padilla-Camberos
ISIván Moisés Sánchez-Hernández
Iván Moisés Sánchez-Hernández
OTOmar Torres
Omar Torres
PRPatricia Ramirez-Rodriguez
Patricia Ramirez-Rodriguez
NMNestor Emmanuel Diaz Martinez
Nestor Emmanuel Diaz Martinez
JFJose Miguel Flores-Fernandez
Jose Miguel Flores-Fernandez
The synthesis and application of nanomaterials as antioxidants and cytotoxic agents has increased in recent years. Biological methods go beyond the chemical and physical synthesis that is expensive and not friendly to the environment. Foodborne pathogens and microorganisms causing candidiasis are responsible of 5–10% hospitalized patients. The nutritional properties of the fruit called pitaya, from the Stenocereus queretaroensis species, have been little explored. Therefore, in this study the phytochemical composition of S. queretaroensis peel was evaluated and silver nanoparticles (AgNPs) were synthesized biologically in an environmentally friendly way by S. queretaroensis peel aqueous extract that contains phytochemicals capable of reducing silver nitrate. The antimicrobial activity of the AgNPs was tested by determining the minimum inhibitory concentration (MIC), minimal bactericidal concentration (MBC) and time-kill kinetics. AgNPs were characterized visually, by UV-visible spectroscopy and TEM. FTIR spectroscopy identified metabolites responsible for the AgNPs formation. AgNPs showed potent antimicrobial activity against gram-negative and gram-positive bacteria, against fungi, and a methicillin-resistant strain of S. aureus. MIC and MBC values were as low as 0.078 and 0.156 μg/mL using AgNPs biosynthesized by S. queretaroensis fruit peel and the time kill assay started a log reduction in CFU/mL at 1 × MIC and 2 × MIC. S. queretaroensis-mediated AgNPs could be the basis for the formulation of biofilms for packaging products or as disinfectants for use on different surfaces.

1 January 2019 in Drug Discovery Today
Verified
Journal Article
Closed access
ACAgustin Cota-Coronado
Agustin Cota-Coronado
PRP. Berenice Ramírez-Rodríguez
P. Berenice Ramírez-Rodríguez
EPEduardo Padilla-Camberos
Eduardo Padilla-Camberos
ÉDÉnstor F. Díaz
Énstor F. Díaz
JFJose M. Flores-Fernández
Jose M. Flores-Fernández
NMNestor Emmanuel Diaz Martinez
Nestor Emmanuel Diaz Martinez